تالیفات

Abstract: Since our first report in 1987 to the XIth EULAR Congress of Rheumatology several reports had proved the efficacy of pulsed cyclophosphamide (PCP) in severe posterior uveitis (PU) and retinal vasculitis (RV) of Behcet's Disease (BD). The aim of this report is to show the outcome of 45 patients who have been followed for more than 2 years. PCP was administered as lg/m2/body surface, once per month, with 0.5 mg ...

Abstract: Posterior uveitis and retinal vasculitis are the most serious lesions­ of ocular Behcet. Pulse cyclophosphamide and cyclosporine A are the most efficient treatment. Oral cytotoxic drugs (cyclophosphamide, chlorambucil , and azathioprine) are less efficient. We present here our first impression on weekly pulsed methotrexate (MTX). MTX was administereted as 7.5 mg weekly in 3 divided doses, every 12 hours Prednisolone was given as 0.5 mg/kg/day. 23 patients with posterior uveitis (PU) ...

Abstract: PCP was administered as 1 g cyclophosphsmide/m2/body surface, once per month, with 0.5mg prednisolone/kg/day, to 71 patients with severe posterior uveitis (PU) and/or retinal vasculitis (RV) , A Disease Activity Index (DAI) was calculated for each section of each eye, before the first PCP and then after each one. When a remission was obtained the gap between, PCP was increased gradually and prednisolone was tapered. If the result remained ...

Abstract: Behcet's Disease (BD) is rather frequent in Iran. Near 200 new cases are seen every year, and this rate is going up every year. Oph­thalmological manifestations are frequent (71%). Anterior uveitis (AU) is seen in 63% of patients. It is characterized by flare and cells in the anterior chamber. Hypopion, the classic lesion of the anterior chamber is transient and rarely seen in ophthalmologic examination. The AU progresses by successive ...

Abstract: PCP as lg/m2/body surface was given once per month, with 0.5 mg prednisolone/kg/day, to 155 patients with sever posterior uveitis (PU) and/ or retinal vasculitis (RV). A Disease Activity Index (DAI), based upon the inflammatory state of the eye, was calculated for each section of each eye before the first PCP and then after each PCP. When a remission was obtained the gap between PCP was increased gradually to 2, ...

Abstract: Ophthalmologic manifestations of BD, especially posterior uveitis and retinal vasculitis are resistant to most treatments, leading to sever loss of vision. Cytotoxic drugs, especially chlorambucil and cyclo­phosphamide (CP) are effective in some patients. In a preliminary report to the XI EULAR Congress of Rheumatology we demonstrated the efficacy of PTCP in these lesions. PTCP was performed by perfusion of 1 g. CP per square meter of body surface in 500 ...

Abstract: PT was performed by 2 methodes: 1- Needle prick. 2-- Intra dermal injection of normal salin. 83 % of BD patients presented a positive PT. Control subjects were composed of 101 healthy person, 46 Rheumatoid Arthritis, 5 Ankylosing Spondylitis, 18 Systemic Lupus Erythematosus (SLE). 3 Sclerodermia, and 1 permatomyositis. Among them 16% presented a positive PT. Only 3% had a positive PT with both needle prick and normal salin method. ...

Abstract: Patients with sever posterior uveitis and/or retinal vasculitis, and un­responsive to oral cytatoxic drugs and/or high doses steroids, were selected for this study. Pulse cyclophosphamide (PCP) was performed by perfusion of 1 g cyclophosphalnide per square meter of body surface in 500 ml of normal saline. PCP was repeated every month after a new evaluation of the patient. 30 mg of prednisolone/day was also given. Actually 102 patients are receiving ...

Abstract: We have reported a 100% association of ocular type of BD with B5 cluster antigens. The HLA results of non ocular type shows respectively 30% and 40% of association with B5 and B5 cluster antigens. These results indicate that B5 cluster antigens are decreased in non ocular patients compared to 62% of normal population. Considering the etiologic fraction for B5 cluster in ocular type patients which was at its maximum ...